Back to results
US 8,278,454 B2Granted
Process for preparing tetrahydroquinoline derivatives
AssigneeMerck Patent GmbH
InventorsUlrich Emde, Oliver Block, Kai Schiemann
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.
Claims23
A process for the manufacture of an enantiomerically enriched or pure compound of formula I:
- wherein
- Ra denotes Hal, cyano, COOH, COOA, A, CF3;
- R1 denotes H, A, Ar, Het, Hal, —(CY2)n—SA, —(CY2)n—SCF3, —(CY2)n—SCN, —(CY2)n—CF3, —(CY2)n—OCF3, R, cycloalkyl, —SCH3, —SCN, —CF3, —OCF3, —OA, —(CY2)n—OH, —(CY2)n—CO2R, —(CY2)n—CN, —(CY2)n-Hal, —(CY2)n—NR2, (CY2)n—OA, (CY2)n—OCOA, —SCF3, (CY2)n—CONR2, —(CY2)n—NHCOA, —(CY2)n—NHSO2A, SF5, Si(CH3)3, CO—(CY2)n—CH3, —(CY2)n—N-Pyrrolidone, (CH2)nNRCOOR, NRCOOR, NCO, (CH2)nCOOR, NCOOR, (CH2)nOH, NR(CH2)nNR2, C(OH)R2, NR(CH2)nOR, NCOR, (CH2)nAr, (CH2)nHet, (CH2)nR, (CH2)nX(CH2)nAr, (CH2)nX(CH2)nHet, (CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nXAr, N[(CH2)nXR]SO2(CH2)nAr, N[(CH2)nNRCOOR]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nNRAr, N[(CH2)nNR2]SO2(CH2)nAr, N[(CH2)nXR]CO(CH2)nHet, N[(CH2)nXR]CO(CH2)nXHet, N[(CH2)nXR]SO2(CH2)nHet, N[(CH2)nNRCOOR]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nNRHet;
- R2, R3 denotes H, A, Hal, OA, OR;
- Y denotes H, A, Hal, OR;
- A denotes Alkyl or Cycloalkyl, wherein one or more H-atoms can be replaced by Hal;
- Hal denotes F, Cl, Br or I;
- R denotes H or A, in the case of geminal groups R together also —(CH2)5—, —(CH2)4— or —(CH2)n—X—(CH2)n, or —(CH2)n—Z—(CH2)n;
- X denotes O, S, NA or NH;
- Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1;
- Z denotes CH2, X, CHCONH2, CH(CH2)nNRCOOR, CHNRCOOR, NCHO, CHCON(R)2, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, NCOR, N(CH2)nAr, N(CH2)nHet, CHR, NR, CH(CH2)nAr, CH(CH2)nHet, CH(CH2)nR, N(CH2)nCOOR, CH(CH2)nX(CH2)nAr, CH(CH2)nX(CH2)nHet, N(CH2)nCON(R)2, NSO2R, CHSO2N(R)2, XCONR(CH2)nN(R)2, NCO(CH2)nAr, NCO(CH2)nXAr, NSO2(CH2)nAr, NCO(CH2)nAr, NCO(CH2)nNRAr, NCO(CH2)nHet, NCO(CH2)nXHet, NSO2(CH2)nHet, NCO(CH2)nNRHet, N(CH2)nNR2CH, CHO(CH2)nN(R)2, CHX(CH2)nN(R)2, or, NCO(CH2)nNR2;
- R6 denotes unsubstituted Ar or Het which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Ar or Het which also may be substituted by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2,
- R7 denotes (C═O)—R, (C═O)—NR2, (C═O)—OR, H or A;
- Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2;
- Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)nCO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2;
- n denotes 0, 1, 2, 3, 4, 5, 6 or 7;
- or a pharmaceutically acceptable tautomer or salt thereof, said process comprising:
- reacting an aniline compound A and an aldehyde B
- with a chiral dihydropyran methylamine compound C
- in the presence of a suitable solvent and a protonic acid or Lewis acid wherein R1 to R6 and Q are as described above.
17 more elements
A process for the manufacture of enantiomerically enriched or pure compounds of formula C:
- wherein
- Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1,
- R1 denotes H, A, Ar, Het, Hal, —(CY2)n—SA, —(CY2)n—SCF3, —(CY2)n—SCN, —(CY2)n—CF3, —(CY2)n—OCF3, R, cycloalkyl, —SCH3, —SCN, —CF3—OCF3, —OA, —(CY2)n—OH, —(CY2)n—CO2R, —(CY2)n—CN, —(CY2)n-Hal, —(CY2)n—NR2, (CY2)n—OA, (CY2)n—OCOA, —SCF3, (CY2)n—CONR2, —(CY2)n—NHCOA, —(CY2)n—NHSO2A, SF5, Si(CH3)3, CO—(CY2)n—CH3, —(CY2)n—N-Pyrrolidone, (CH2)nNRCOOR, NRCOOR, NCO, (CH2)nCOOR, NCOOR, (CH2)nOH, NR(CH2)nNR2, C(OH)R2, NR(CH2)nOR, NCOR, (CH2)nAr, (CH2)nHet, (CH2)nR, (CH2)nX(CH2)nAr, (CH2)nX(CH2)nHet, (CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nXAr, N[(CH2)nXR]SO2(CH2)nAr, N[(CH2)nNRCOOR]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nNRAr, N[(CH2)nNR2]SO2(CH2)nAr, N[(CH2)nXR]CO(CH2)nHet, N[(CH2)nXR]CO(CH2)nXHet, N[(CH2)nXR]SO2(CH2)nHet, N[(CH2)nNRCOOR]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nNRHet,
- Y denotes H, A, Hal, or OR,
- A denotes Alkyl or Cycloalkyl, wherein one or more H-atoms can be replaced by Hal
- Hal denotes F, Cl, Br or I,
- R denotes H or A, in the case of geminal groups R together also —(CH2)5—, —(CH2)4— or —(CH2)n—X—(CH2)n, or —(CH2)n—Z—(CH2)n,
- X denotes O, S, NH or NA,
- Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1,
- Z denotes CH2, X, CHCONH2, CH(CH2)nNRCOOR, CHNRCOOR, NCHO, CHCON(R)2, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, NCOR, N(CH2)nAr, N(CH2)nHet, CHR, NR, CH(CH2)nAr, CH(CH(CH2)nHet, CH(CH2)nR, N(CH2)nCOOR, CH(CH2)nX(CH2)nAr, CH(CH2)nX(CH2)nHet, N(CH2)nCON(R)2, NSO2R, CHSO2N(R)2, XCONR(CH2)nN(R)2, NCO(CH2)nAr, NCO(CH2)nXAr, NSO2(CH2)nAr, NCO(CH2)nAr, NCO(CH2)nNRAr, NCO(CH2)nHet, NCO(CH2)nXHet, NSO2(CH2)nHet, NCO(CH2)nNRHet, N(CH2)nNR2CH, CHO(CH2)nN(R)2, CHX(CH2)nN(R)2, NCO(CH2)nNR2,
- Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2,
- Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2, and
- n denotes 0, 1, 2, 3, 4, 5, 6 or 7,
- as well as their pharmaceutically acceptable tautomers and salts,
- said process comprising:
- A)
- treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give enantiomerically enriched or pure dihydropyran methylamine salts;
- and optionally using a base to obtain the free base from the dihydropyran methylamine salts;
- or
- B)
- treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
- optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
- reacting the resulting compound with ClC(O)R1 or ClSO2R1 in the presence of a non nucleophilic base in a polar solvent;
- or
- C)
- treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
- optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
- reacting the resulting compound with a primary amine NH2R1 with CDI in a solvent.
25 more elements
Dependencies are inferred from the claim text.